Study study type PathologyT1T0Patientssample sizesROB Results deaths (OS) Eprogression or deaths (PFS) ERFS/DFS E

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone
KEYNOTE-042 (PDL1>50%), 2019
  NCT02220894
RCTmNSCLC - L1 - PDL1 positivepembrolizumabplatinium based chemotherapypreviously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 50% or greater299 / 300some concern
conclusif demonstrated-31% -19%
KEYNOTE-042 (PDL1>20%), 2019
  NCT02220894
RCTmNSCLC - L1 - PDL1 positivepembrolizumabplatinium based chemotherapypreviously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 20% or greater413 / 405some concern
conclusif demonstrated-23% -6%
KEYNOTE-042 (PDL1>1%), 2019
  NCT02220894
RCTmNSCLC - L1 - PDL1 positivepembrolizumabplatinium based chemotherapypreviously untreated, locally advanced or metastatic non-small-cell lung cancer with a PD-L1 TPS of 1% or greater637 / 637some concern
conclusif demonstrated-19% 7%
KEYNOTE-024 (PDL1>50%), 2016
  NCT02142738
RCTmNSCLC - L1 - PDL1 positivePembrolizumabICC platinum-based chemotherapies regimenspatients who had previously untreated advanced stage IV NSCLC with PD-L1 expression on at least 50% of tumor cells154 / 151some concern
conclusif demonstrated-40% demonstrated-50%

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
pembrolizumab (10mg/kg)
KEYNOTE-010 (P:10 mg/kg), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 10 mg/kgdocetaxelpatients with previously treated (one line or more) non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells346 / 343high
conclusif demonstrated-39% -21%
KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 10 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells151 / 152high
conclusif demonstrated-50% demonstrated-41%
pembrolizumab (2mg/kg)
KEYNOTE-010 (P: 2mg/kg), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 2 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells344 / 343high
conclusif demonstrated-29% -12%
KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016
  NCT01905657
RCTmNSCLC - L2 - PDL1 positivepembrolizumab 2 mg/kgdocetaxelpatients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells139 / 152high
conclusif demonstrated-46% demonstrated-41%